Internal Medicine, Hematology & Oncology · Nashville, TN
NPI
1144261231
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3601 the Vanderbilt Clinic
Nashville, TN, 37232
Phone (615) 936-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$47K
470 services
Medicare patients, 2024
192
Average age 73
Drug cost, 2024
$6.6M
833 prescriptions
Company payments, 2025
$57K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Brian I Rini was code 99215 (office e&m - established), 332 times for 141 patients. In total Brian I Rini billed 470 services in 9 codes, and Medicare paid $47K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 332 | 141 | $100.63 | $33K |
| 99205 Office E&M - New | Facility | 45 | 45 | $137.06 | $6,168 |
| 99214 Office E&M - Established | Facility | 29 | 23 | $72.98 | $2,116 |
| 99232 Hospital E&M - Subsequent | Facility | 20 | 11 | $61.49 | $1,230 |
| 99222 Hospital E&M - Initial | Facility | 12 | 12 | $85.87 | $1,030 |
| 99238 Hospital Discharge Management | Facility | 11 | 11 | $57.33 | $631 |
By year: 2022 $40K for 420 services; 2023 $45K for 468 services; 2024 $47K for 470 services.
Medicare prescription drug claims, 2024
In 2024, the drug Brian I Rini prescribed most often to Medicare patients was Abiraterone Acetate, with 128 prescriptions and refills. In total Brian I Rini wrote 833 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Abiraterone Acetate Generic | 128 | 132 | 16 | $328K |
| Prednisone Generic | 105 | 147 | 25 | $494 |
| Orgovyx Relugolix | 101 | 101 | 14 | $256K |
| Cabometyx Cabozantinib S-Malate | 86 | 86 | 12 | $1.8M |
| Xtandi Enzalutamide | 58 | 58 | Under 11 | $803K |
| Welireg Belzutifan | 47 | 47 | Under 11 | $1.3M |
| Fotivda Tivozanib Hcl | 28 | 28 | Under 11 | $771K |
| Lenvima Lenvatinib Mesylate | 24 | 24 | Under 11 | $557K |
| Inlyta Axitinib | 23 | 23 | Under 11 | $384K |
| Oxycodone Hcl Generic | 21 | 21 | 12 | $277 |
| Levothyroxine Sodium Generic | 21 | 45 | Under 11 | $152 |
| Nubeqa Darolutamide | 21 | 21 | Under 11 | $251K |
| Eliquis Apixaban | 17 | 19 | Under 11 | $12K |
| Tamsulosin Hcl Generic | 16 | 24 | Under 11 | $83.4 |
| Ondansetron Hcl Generic | 14 | 14 | 12 | $75.62 |
Brand drugs: 440 claims; generic drugs: 393 claims; opioid claims: 32.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Brian I Rini $57K ($57K in general payments such as food, travel and fees) from 18 companies. The largest payer was Merck Sharp & Dohme LLC with $26K.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 15 | $26K |
| Eisai Inc. 4523.T | 5 | $12K |
| GlaxoSmithKline, LLC. GSK | 1 | $7,125 |
| Eisai Co., Ltd. 4523.T | 1 | $4,850 |
| Pfizer Inc. PFE | 3 | $2,323 |
| AstraZeneca UK Limited AZN | 1 | $1,713 |
| Janssen Biotech, Inc. JNJ | 1 | $1,388 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $1,290 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $490 |
| Exelixis Inc. EXEL | 1 | $172 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.